Engineered G-alpha Proteins for High-Throughput RGS Assays
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for screening modulators of RGS GAP catalytic activity are hindered by the complexity and limitations of existing assays, such as the single-turnover GTPase assay and reliance on reconstituted GPCR/G protein complexes, which are not suitable for high-throughput screening (HTS) due to their low throughput and requirement for radioactive materials.
Innovation Solution
Genetically engineered G-alpha proteins with specific mutations that alter the relative rates of GTPase and GDP dissociation, allowing for the use of steady-state enzymatic assays to monitor changes in GTPase activity and enabling the detection of RGS GAP activity using biochemical assays.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If single-turnover GTPase assay or reconstituted GPCR/G protein complexes are used to screen modulators of RGS GAP catalytic activity, then measurement precision can be maintained, but productivity is low and device complexity is high due to requirement for radioactive materials and complex reconstitution procedures
Solution Approach 1:
The patent mutates conserved amino acid residues in the Gα protein (specifically the arginine in the P-loop and threonine in switch region II) to alter the kinetic parameters of the GTPase reaction. These mutations change the relative rates of GTP hydrolysis and GDP dissociation, enabling steady-state conditions to be achieved without requiring complex reconstituted systems or radioactive markers, thus enabling high-throughput screening while maintaining detection accuracy
2Productivity
If genetically engineered G-alpha proteins with specific mutations are used, then productivity increases by enabling steady-state enzymatic assays for HTS, but manufacturing precision requirements increase due to need for specific amino acid substitutions
Solution Approach 1:
The patent introduces specific point mutations at conserved positions in the Gα protein sequence (arginine in P-loop, threonine in switch region II) to fundamentally change the kinetic behavior of the protein. These precise amino acid substitutions enable the protein to function under steady-state conditions with altered GDP dissociation and GTP hydrolysis rates, making it suitable for HTS applications while maintaining relatively simple production requirements
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the detection of RGS-catalyzed stimulation of GTP hydrolysis in a robust HTS format, facilitating the identification of modulators of RGS GAP activity and potentially leading to new drug discoveries for neurological disorders.
Implementation Method 1
The engineered protein is a mutant Gα protein, which in some examples contains alterations of at least one, and preferably two or more, highly conserved amino acid residues... The mutations described here yield an unexpectedly high effect on Gα function both in terms of GTPase activity (GTP hydrolysis) and GDP recycling.
Implementation Method 2
RGS proteins accelerate the rate of Gα-catalyzed GTP hydrolysis by as much as 100-fold, which provides the basis for an in vitro screening assay
Data Source
AI summary
The present invention relates to novel engineered Ga proteins and assay methods of using such proteins to advance drug discovery. Engineered Ga proteins described by the invention contain alterations of at least one and preferably two or more amino acid residues that are highly conserved among all four subfamilies of Ga proteins. A preferred engineered protein disclosed here is a double mutant, Gαπ R178M A326S. This specific combination of mutations yields an unexpectedly amplified effect on Ga function both in terms of GTPase activity (GTP hydrolysis) and GDP dissociation. This synergistic effect may have a profound influence on the way GPCR signaling pathways are examined for the development of new pharmacotherapies, particularly in the field of central nervous system disorders such as Parkinson's disease.